Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Metagenomi Inc (MGX)

Metagenomi Inc (MGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 66,809
  • Shares Outstanding, K 37,533
  • Annual Sales, $ 52,300 K
  • Annual Income, $ -78,060 K
  • EBIT $ -92 M
  • EBITDA $ -95 M
  • 60-Month Beta 0.49
  • Price/Sales 1.28
  • Price/Cash Flow N/A
  • Price/Book 0.38

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.57
  • Number of Estimates 2
  • High Estimate -0.46
  • Low Estimate -0.69
  • Prior Year -0.63
  • Growth Rate Est. (year over year) +9.52%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4700 +21.09%
on 11/21/25
2.2800 -21.93%
on 11/06/25
-0.4800 (-21.24%)
since 11/05/25
3-Month
1.4700 +21.09%
on 11/21/25
3.9500 -54.94%
on 10/16/25
-0.1300 (-6.81%)
since 09/05/25
52-Week
1.2300 +44.72%
on 04/04/25
4.9200 -63.82%
on 12/10/24
-0.0700 (-3.78%)
since 12/05/24

Most Recent Stories

More News
Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference

EMERYVILLE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative...

MGX : 1.7800 (-0.56%)
Metagenomi to Present at Jefferies Global Healthcare Conference in London

EMERYVILLE, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative...

MGX : 1.7800 (-0.56%)
Metagenomi: Q3 Earnings Snapshot

Metagenomi: Q3 Earnings Snapshot

MGX : 1.7800 (-0.56%)
Metagenomi Reports Third Quarter 2025 Financial Results and Announces Strategic Pipeline Prioritization and Leadership Updates

New MGX-001 preclinical data supports advancement into clinical development;  Demonstrated curative FVIII activity in non-human primates Prioritized later-stage preclinical pipeline including...

MGX : 1.7800 (-0.56%)
Metagenomi Presents New Preclinical Data from MGX-001 Hemophilia A Program Supporting Advancement into Clinical Development

MGX-001 demonstrated curative FVIII activity in non-human primates Pre-IND regulatory meeting expected in Q4 2025 with investigational new drug (IND) and clinical trial application (CTA) submissions...

MGX : 1.7800 (-0.56%)
Metagenomi Regains Control After Affini-T Agreement Termination

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest...

MGX : 1.7800 (-0.56%)
Metagenomi: Q2 Earnings Snapshot

Metagenomi: Q2 Earnings Snapshot

MGX : 1.7800 (-0.56%)
Metagenomi Reports Business Updates and Second Quarter 2025 Financial Results

Presented three abstracts at American Society of Gene & Cell Therapy (“ASGCT”) demonstrating early proof-of-concept data across multiple gene editing technologies Well capitalized with $ 205.0...

MGX : 1.7800 (-0.56%)
Metagenomi Appoints Laurence Reid, PhD to its Board of Directors

EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), a precision genetic medicines company committed to developing curative therapeutics for patients...

KALV : 16.43 (+0.18%)
MGX : 1.7800 (-0.56%)
Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025

MGX : 1.7800 (-0.56%)

Business Summary

Metagenomi Inc. is a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox. Metagenomi Inc. is based in EMERYVILLE, Calif.

See More

Key Turning Points

3rd Resistance Point 1.9133
2nd Resistance Point 1.8667
1st Resistance Point 1.8233
Last Price 1.7800
1st Support Level 1.7333
2nd Support Level 1.6867
3rd Support Level 1.6433

See More

52-Week High 4.9200
Fibonacci 61.8% 3.5104
Fibonacci 50% 3.0750
Fibonacci 38.2% 2.6396
Last Price 1.7800
52-Week Low 1.2300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar